Crossmark

Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy

Crossref DOI link: https://doi.org/10.1007/s10120-023-01445-7

Published Online: 2023-11-25

Published Print: 2024-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Eo Jin

Chae, Heejung

Park, Young-Soo

Ryu, Min-Hee

Kim, Hyung-Don

Shin, Junyoung

Park, Yang Soon

Moon, Mee Sun

Kang, Yoon-Koo https://orcid.org/0000-0003-0783-6583
License Information

Text and Data Mining valid from 2023-11-25

Version of Record valid from 2023-11-25
More Information

Article History

Received: 23 July 2023

Accepted: 20 October 2023

First Online: 25 November 2023

Declarations

:

: Nothing directly related to this work. Out of this work, YKK has served as a consultant for Liscure, ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, and Merck (MSD). MHR received an honorarium and served on the advisory boards of Ono Pharmaceutical, BMS, MSD, Lily, Taiho, Novartis, Daiichi Sankyo, and AstraZeneca, and served as a consultant for DAEHWA Pharmaceutical, BMS, Lily, and Ono Pharmaceutical.

Document is current

Any future updates will be listed below